Evidence map›Paper›PMID 26242979›Full record

ArticleBMC neurology2015

Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report.

Kaori Morimoto, Kei Nagaoka, Akira Nagai, Hirofumi Kashii, Masakiyo Hosokawa, Yukitoshi Takahashi, Takuo Ogihara, Masaya Kubota

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Antiviral Activity ofJournal of microbiology and biotechnology · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kaori MorimotoDepartment of Pharmacology, Graduate School, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki-city, Gunma, Japan. morimoto@tohoku-pharm.ac.jp.
Kei NagaokaDepartment of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. nagaoka-k@khe.biglobe.ne.jp.
Akira NagaiDepartment of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. nagai-ak@ncchd.go.jp.
Hirofumi KashiiDivision of Neurology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. kashii-tky@umin.ac.jp.
Masakiyo HosokawaFaculty of Pharmaceutical Sciences, Chiba Institute of Science, 15-8 Shiomi-cho, Choshi-city, Chiba, Japan. masakiyo@cis.ac.jp.
Yukitoshi TakahashiDepartment of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama 886, Aoi-ku, Shizuoka, 420-8688, Japan. yukito@hosp.go.jp.
Takuo OgiharaDepartment of Pharmacology, Graduate School, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki-city, Gunma, Japan. togihara@takasaki-u.ac.jp.
Masaya KubotaDivision of Neurology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. mkmegped@opal.plala.or.jp.
National Center For Child Health and Development · JPTakasaki University of Health and Welfare · JPChiba Institute of Science · JPNational Epilepsy Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuropsychiatric side effects of oseltamivir occur occasionally, especially in infants and young patients, but nothing is known about possible contributory factors. CASE PRESENTATION: We report a case of a 15-year-old Japanese female with influenza infection who developed abnormal psychiatric symptoms after administration of standard doses of oseltamivir. She had no history of neurological illness, had never previously taken oseltamivir, and had not developed psychiatric reactions during previous influenza infection. Her delirium-like symptoms, including insomnia, visual hallucinations, and a long-term memory deficit, disappeared after cessation of oseltamivir and administration of benzodiazepine. Detailed assessment was performed, including neurological examination (electroencephalogram, brain magnetic resonance imaging, single photon emission computed tomography with 99mTc-ethyl cysteinate dimer and with (123)I-iomazenil, cerebrospinal fluid analysis and glutamate receptor autoantibodies), drug level determination and simulation, and genetic assessment (OAT1, OAT3, CES1, Neu2).

conclusionsAbnormal slowing in the electroencephalogram, which is characteristic of influenza-associated encephalopathy, was not observed in repeated recordings. The serum level determination of active metabolite Ro 64-0802 determined at 154 h after final dosing of oseltamivir was higher than the expected value, suggesting delayed elimination of Ro 64-0802. Thus, abnormal exposure to Ro 64-0802 might have contributed, at least in part, to the development of neuropsychiatric symptoms in this patient. The score on Naranjo's adverse drug reaction probability scale was 6. Mutation of c.122G > A (R41Q) in the sialidase Neu2 gene, increased CSF glutamate receptor autoantibodies, and limbic GABAergic dysfunction indicated by SPECT with (123)I-iomazenil were found as possible contributory factors to the CNS side effects.

Indexed as

AdolescentAntiviral AgentsFemaleHallucinationsHumansInfluenza, HumanMemory DisordersMental DisordersOseltamivirSleep Initiation and Maintenance DisordersAntiviral AgentsOseltamivir

Identifiers

PMID26242979
PMCPMC4526296
OpenAlexW1941584562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.